--- title: "Weekly Recap | DH.US +30.86%, consensus target above spot" type: "News" locale: "en" url: "https://longbridge.com/en/news/298097172.md" description: "Definitive Healthcare (DH) climbed 30.86% this week to close at $1.05, outpacing the S&P 500 by about 30.77 percentage points. The move was a sharp early thrust followed by a high-level consolidation. Monday saw a surge from around $0.80 to $0.95; Tuesday eased to $0.90. Wednesday brought a notable volume spike to roughly 8.7 million shares and an intraday high of $1.22, the top of the 60-session range. Thursday and Friday then held between $1.02 and $1.07, closing at $1.05." datetime: "2026-09-05T06:41:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298097172.md) - [en](https://longbridge.com/en/news/298097172.md) - [zh-HK](https://longbridge.com/zh-HK/news/298097172.md) generator: "portal-rs" --- # Weekly Recap | DH.US +30.86%, consensus target above spot ## The Week Definitive Healthcare (DH) climbed 30.86% this week to close at $1.05, outpacing the S&P 500 by about 30.77 percentage points. The move was a sharp early thrust followed by a high-level consolidation. Monday saw a surge from around $0.80 to $0.95; Tuesday eased to $0.90. Wednesday brought a notable volume spike to roughly 8.7 million shares and an intraday high of $1.22, the top of the 60-session range. Thursday and Friday then held between $1.02 and $1.07, closing at $1.05. The weekly low of $0.795 never broke below the prior close, leaving the week’s shape as an upward breakout with range-bound follow-through. ## Key Events The week carried two company-specific developments tied to governance. On Wednesday, 2 September, Definitive Healthcare named Clay Ritchey as CEO and added him to the board. That evening, a special board committee confirmed receipt of a going-private proposal from Advent International. Both arrived on the same session, the day the stock jumped from around $1.02 to the weekly high of $1.22 on heavy volume, suggesting a concentrated market reaction to the leadership change and potential take-private interest. Four other filings this week were treated as routine and excluded from the material events. ## Analyst Ratings Across 7 brokers covering the stock, 1 rates it buy, 5 hold and 1 under, with no sell ratings. The consensus rating is hold. The consensus target sits at $1.90, about 80.95% above the current $1.05, with the target range stretching from $1.00 to $3.00 — a wide spread that points to split views on valuation. Within 32 healthcare information services names, DH ranks 12th by industry rating, against an industry average of 8 and a median of 6 covering brokers. ## The Week Ahead Macro data is dense next week. Tuesday, 8 September brings the US NFIB small business optimism index, with a prior reading of 99.8. Thursday, 10 September is the main event: initial jobless claims (prior 206, forecast 205), final demand PPI and its core measures, existing home sales at an annualised rate, wholesale sales, and EIA natural gas inventory change. For DH itself, no new earnings or company events appear on the calendar, so the take-private story remains the key watch item, even though the timeline for further disclosure is not shown in the calendar. ## In Short The week’s sharp gain coincided with a CEO appointment and a going-private proposal, on volumes well above the norm. The analyst picture is centred on hold, with a consensus target above spot but a wide target range that signals divergent views; valuation shows a negative P/E and a price-to-book around 1.04x. On the latest session, large-lot capital flows leaned net inflow, but that is a single-day snapshot and cannot be stretched into a weekly trend. What matters from here is whether the take-private proposal gets further detail and whether the concentrated macro releases next week sustain the market’s current activity. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [DH.US](https://longbridge.com/en/quote/DH.US.md) ## Related News & Research - [Definitive Healthcare Q3 revenue falls; withholds guidance](https://longbridge.com/en/news/304532612.md) - [Xiaomi delivers 50,168 cars in October as EREVs account for over half of total](https://longbridge.com/en/news/304842555.md) - [CoreWeave Q3 Earnings Preview: Revenue Expected to Grow 159%, Debt and Financing Costs in Focus, Wall Street's Top Price Target at $278](https://longbridge.com/en/news/304812583.md) - [‘The Worst May Not Be Over,’ Says Investor About Rocket Lab Stock](https://longbridge.com/en/news/304905914.md) - [House Democratic leader says lawmakers needs answers on Nvidia, wants China chip restrictions](https://longbridge.com/en/news/304905260.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**